Loading
A phase 3 trial testing GR1803 in multiple myeloma, now recruiting.
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07452198, led by Genrix (Shanghai) Biopharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multicenter, Open-Label, Randomised Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors. Planned enrolment is 358 participants (estimated). The study started in 2026-03-09 and primary completion is expected in 2029-03. No results have been posted on ClinicalTrials.gov.
Shares Genrix Bio, GR1803, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.